ArticleBMC infectious diseases2026
Reconstructive, functional and psychological outcomes in invasive group A streptococcal soft tissue infections: a 10-year retrospective cohort study 2013-2022.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStudies have identified significant morbidity and mortality with necrotising soft tissue infections relating to invasive group A Streptococcus (iGAS). However, no studies have analysed the reconstructive, functional and psychological outcomes of invasive group A Streptococcus infections across its clinical spectrum, including the more common non-necrotising presentations. This study was a retrospective cohort study that aimed to review as primary outcomes the management, reconstructive burden and functional outcomes of soft tissue iGAS infections at a tertiary-care U.K. Plastic Surgery unit between 2013 and 2022. The secondary outcome was to identify associations between patient factors and limb amputation and mortality.
methodsAll positive iGAS cultures isolated in patients aged 16 and over were identified. Medical records, operative records, and microbiology samples were examined.
results96 cases of iGAS were identified in 95 patients over the study period. 63 patients (66%) were male; 34 patients (36%) were current smokers; and 35 patients (37%) were immunocompromised, including 18 patients (19%) with diabetes. 88 cases (92%) affected the upper or lower limbs, with 11 cases (13% of limb iGAS) requiring amputation of the involved digit or limb. Reconstructive surgery was performed in 15 cases (16%), requiring a mean number of 3.7 ± 1.88 operations. Reconstruction methods involved acelluar dermal matrices and/or skin grafts (14 cases; 15%) and locoregional flaps (8 cases; 8.3%). At follow up, 13 cases (14%) had functional complications relating to their iGAS episode, including neuropathic pain and limited movement. Mortality was 5.2% (5 patients) within the index admission and 7.3% (7 patients) within 90 days. Diabetes was significantly associated with 90-day mortality (p = 0.023; odds ratio [OR] 7.05, 95% confidence interval [CI] 1.41–35.00) and amputation (p = 0.033; OR 4.51, 95% CI 1.19–17.19). Other systemic comorbidities were not significantly associated with mortality or amputation.
conclusionsSoft tissue iGAS infections principally affect the limbs and require multimodal management to mitigate the high rates of infection-related morbidity and mortality. Diabetes is significantly associated with higher amputation and mortality rates in our study population. Appropriate services should be in place to manage long-term functional disability and mental health morbidity after iGAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.